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The  ﬁtness  cost  of antibiotic  resistance  in  the absence  of  treatment  raises  the  possibility  that  prudent
use  of  drugs  may  slow  or reverse  the  rise  of resistance.  Unfortunately,  compensatory  mutations  that
lower  this  cost  may  lead  to entrenched  resistance.  Here,  we  develop  a mathematical  model  of  resistance
evolution  and  compensatory  mutation  to determine  whether  reversion  to  sensitivity  can  occur,  and  how
disease control  might  be  facilitated  by  a second-line  therapy.  When  only  a single  antibiotic  is  available,
sensitive  bacteria  reach  ﬁxation  only  under  treatment  rates  so  low  that  hardly  any  cases  are  treated.
We  model  a scenario  in which  drug  sensitivity  can be  accurately  tested  so  that  a second-line  therapy  is
administered  to resistant  cases.  Before  the  rise  of resistance  to the  second  drug,  disease  eradication  is
possible  if resistance  testing  and  second-line  treatment  are  conducted  at a high  enough  rate.  However,  ifompensatory mutation
ost of resistance
double  drug  resistance  arises,  the  possibility  of disease  eradication  is greatly  reduced  and  compensated
resistance  prevails  in most  of  the parameter  space.  The  boundary  separating  eradication  from  ﬁxation
of  compensated  resistance  is strongly  inﬂuenced  by  the  underlying  basic  reproductive  number  of the
pathogen  and  drug  efﬁcacy  in  sensitive  cases,  but depends  less  on the  resistance  cost  and  compensation.
When  double  resistance  is possible,  the  boundary  is  affected  by the  relative  strengths  of  resistance  against
the  two drugs  in  the  double-resistant-compensated  strain.ntroduction
The emergence and spread of antimicrobial resistance con-
inues to be a major public health problem (Andersson and
ughes, 2010; Maisnier-Patin and Andersson, 2004). Resistance
o all major classes of antimicrobial drugs is increasing (Gandhi
t al., 2010; Zhang et al., 2011; Prabaker and Weinstein, 2011;
ughes and Andersson, 2012). For example, the frequency of
iproﬂoxacin resistance in Neisseria gonorrhoeae increased rapidly
n the period 1998–2007 (Goldstein et al., 2012). An important
tep in addressing this problem is to understand the population
ynamics of resistance to prevent epidemics of uncontrollable
isease in the future (Unemo and Shafer, 2011). This problem
as stimulated much research into understanding drug resis-
ance dynamics (Bonhoeffer et al., 1997; Bergstrom and Feldgarden,
008; Lenski, 1998; Levin et al., 1997; Austin et al., 1997, 1999;
ang and Lipsitch, 2006; Boni and Feldman, 2005). Modelling
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ersity of New South Wales, NSW 2052, Australia. Tel.: +61 2 9385 2038;
ax:  +61 2 9385 1483.
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these dynamics enables the evaluation of alternative schemes for
deploying drugs in a population with the aim of optimising those
strategies (Bergstrom et al., 2004; Austin et al., 1997; Hansen and
Day, 2011).
The observation that resistance comes with a cost in the
absence of the drug has raised the possibility of reversion to
sensitivity if antibiotics are used prudently. Unfortunately, how-
ever, this cost of resistance can be overcome by mutations that
reduce the cost (Schrag and Perrot, 1996; Lenski, 1998; Reynolds,
2000; Andersson and Hughes, 2010; Maisnier-Patin and Andersson,
2004). The ultimate success of resistant strains of pathogens with
compensatory mutations depends on ﬁtnesses of the strains in both
the presence and absence of antibiotics because they evolve in a
temporally heterogeneous environment (Schulz zur Wiesch et al.,
2010; Tanaka and Valckenborgh, 2011). In the absence of effective
strategies for control of resistance it may  be only a matter of time
before a compensated resistant strain of a pathogen emerges and
spreads (Handel et al., 2006).
Despite the growing recognition of compensatory mutation
as an important factor in managing drug resistance, little work
has been done to understand its impact at the population level.
Wijngaarden et al. (2005) considered the dynamics of resistance
to a pesticide with the possibility of compensatory mutation.
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Table  1
Variables of the simple model.
Variable Description
X Susceptible individuals
US Infections with sensitive strain, untreated
UR Infections with resistant strain, untreated
UC Infections with compensated resistant strain, untreated
T Infections with sensitive strain, treated
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Fig. 1. Model structure for simple model. Variables and rates are as deﬁned in
Tables 1 and 2. Here, the asterisks (*) indicate transmission of the sensitive, resistantS
TR Infections with resistant strain, treated
TC Infections with compensated resistant strain, treated
esistance reaches ﬁxation when the use of pesticides is high rel-
tive to the cost of resistance, which can evolve to be lower. This
rocess is accelerated by recombination. Day and Gandon (2012)
lso considered the effect of recombination on the evolution of mul-
ilocus drug resistance. Handel et al. (2006) studied the emergence
f compensatory mutation as an irreversible conversion process.
sing a stochastic model that study characterised the probability
f emergence of compensated resistant strains of a pathogen and
he distribution of the time until emergence.
Given the crucial impact of compensatory mutation on ris-
ng frequencies of drug resistance, it will become increasingly
mportant to investigate strategies to combat resistance while still
reating cases of disease. In particular, the effective use of second-
ine drugs may  become important. The disease may  be controllable
y second-line therapies if it is practical to test whether newly
etected cases are resistant to the ﬁrst treatment. Here, we  develop
n epidemiological model of drug resistance and compensatory
utation in which two alternative treatments are available. The
econd-line therapy is only used when a new case is tested and
ound to be resistant to the ﬁrst drug. We  use the model to ask
hether any level of treatment would allow sensitive bacteria to
revail; second, we examine what levels of treatment would erad-
cate disease, under the availability of the second-line drug.
odels of drug resistance evolution
We  introduce deterministic models based on an SIS model that
s applicable to gonorrhea dynamics (Hethcote and Yorke, 1984),
xtended to include antimicrobial treatment, evolution of resis-
ance to treatment and compensatory mutation lowering the cost
f resistance. We  begin with a simple model in which resistance
volves against only the primary therapy. We later relax this
ssumption in an extended model to allow resistance to both drugs.
The simple model includes three pathogen strains, namely a
rug-sensitive strain S, a resistant mutant R carrying a ﬁtness cost
f resistance, and a compensated resistant strain C with a mutation
hat lowers this cost. Susceptible individuals, whose frequency is
racked with X, can be infected with one of the three pathogen
trains. All cases receive treatment at the same rate, and both
ntreated (labelled U) and treated (labelled T) individuals return
o the susceptible pool when they recover. Thus our infected pop-
lation is divided into six disjoint subpopulations according to the
train they are infected by (S, R or C) and whether they are treated
T or U). Table 1 summarises the dynamic variables and Fig. 1 gives
 schematic of the process. Infections can convert among classes
ue to within-host mutation and ﬁxation, as described in detail
ater.
odelling transmission and recovery
The transmission parameters are ˇS, ˇR, ˇC respectively for drug
ensitive, resistant and compensated (and resistant) strains. Let-
ing  ˇ be the baseline transmission of the sensitive strain, we
et a cost c of resistance reﬂected in transmission and compen-
ation (1 − ) of this cost so that the three infection parametersand compensated strains, whose forces of infection are ˇS(US + TS), ˇR(UR + TR) and
ˇC(UC + TC), respectively.
are given by ˇS = ˇ, ˇR =  ˇ (1 − c) and ˇC =  ˇ (1 − c). The compound
parameter c is the residual cost of resistance after compensa-
tion has occurred. Infected untreated individuals recover at rate
 per individual per unit time. Let  be the rate per individual at
which a case is detected and treated. As an alternative parametri-
sation we also deﬁne f = /( + ) to be the proportion of cases
treated.
To parametrise recovery under treatment, ﬁrst consider the
case in which a single class of antibiotic is available. The dura-
tion of infection with the sensitive strain is reduced by  under
treatment. Resistance increases the duration of treated infec-
tion through parameter b while infection with the compensated
resistant strain lengthens the duration through parameter k. Specif-
ically, if only a single treatment is available, the recovery rates for
treated classes are /(1 − ), /(1 − (1 − b)) and /(1 − (1 − k))
respectively for S, R and C. We  now generalise these recovery rates
for when there is an alternative, second-line treatment. We  model
a situation in which each new detected case is tested for resis-
tance to the ﬁrst drug, and if resistance is found, the second-line
therapy is used. We  assume for simplicity that this second-line
therapy is always effective and resistance does not evolve to it.
Let  be the proportion of detected cases that are tested for
drug resistance. The recovery rates for treated cases are then
S =

1 − 
R = (1 − )

1 − (1 − b) + 

1 − 
C = (1 − )

1 − (1 − k) + 

1 −  .
Conversion among resistance states
The conversion rates between strains depend on both muta-
tion and within-host ﬁxation, which in turn depend on selective
pressures. Let  be proportional to the mutation rate per individual
per gene per unit time. The probability of ﬁxation is approximately
twice the selective coefﬁcient (Haldane, 1927); we therefore allow
 to subsume the factor of 2 and derive the selective coefﬁcients
in each of the four within-host conversion processes shown in
Fig. 1.
To determine how 1 relates to the ﬁtness parameters, ﬁrst note
that in the absence of the drug the ﬁtness values of sensitive rel-
ative to resistant strains are in the ratio (1:1 − c). In a within-host
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Table 2
Primary parameters of the simple model.
Symbol Description Value/range
R˜0,S Basic Reprod. Num., sensitives (no treatment) 2
  Recovery rate when untreated (/case /year) 2
f  Proportion cases detected and treated (0, 1)
  Proportion treated cases tested for resistance (0, 1)
  Mutation rate ×2 (/case /year) 10−6
 Drug effectiveness in sensitive cases 0.9
c Cost of resistance (no treatment) 0.1
 One minus compensation (no treatment) 0.1
maximum at a low treatment rate, but further increasing the frac-
tion of cases detected ensures that the infection prevalence reduces
to zero (Fig. 4B). This reduction is due to the application of resis-
tance testing and the second-line therapy.
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opulation dominated by resistant bacteria, a sensitive mutant has
 selective coefﬁcient of 1/(1 − c) − 1 = c/(1 − c) and so we  set
1 =
c
1 − c .
pplying the same reasoning to the other within-host conversion
ates we obtain
2 =
c(1  − )
1 − c
3 =
b
1 − 
4 =
(k  − b)
1 − (1 − b) .
ynamics of the simple model
The dynamics of the model are described by the following sys-
em of differential equations.
dX
dt
= −ˇSX(US + TS) + US + STS − ˇRX(UR + TR) + UR + RTR
−ˇCX(UC + TC ) + UC + CTC
dUS
dt
= ˇSX(US + TS) + 1UR − US − US
dUR
dt
=  ˇRX(UR + TR) − 1UR − 2UR − UR − UR
dUC
dt
=  ˇCX(UC + TC ) + 2UR − UC − UC
dTS
dt
= US − 3TS − STS
dTR
dt
= UR + 3TS − 4TR − RTR
dTC
dt
=  UC + 4TR − CTC.
To analyse this system numerically, we used R (R Core Team,
013) with the deSolve package (Soetaert et al., 2010). The val-
es of the epidemiological parameters  and R˜0,s were taken from
andel et al. (2006) and Brunham et al. (1994). The baseline trans-
ission parameter  ˇ was set as R˜0,S and the treatment rate  was
et using the fraction of cases treated, f = /( + ). The mutation
ate was set to  = 10−6 which is based on a per-generation rate
f 10−9 (Maness and Sparling, 1973) and assuming around 1000
enerations per year. We  set the drug efﬁcacy to  = 0.9 to increase
he recovery rate 10 fold. The resistance parameters were set to
 = 0.7, k = 0.9 to reﬂect a high degree of resistance. The cost of
esistance was set to c = 0.1 which is in line with empirical mea-
urements (Schrag and Perrot, 1996), and compensation was set
o 1 −  = 0.9 to specify a large reduction in the cost of resistance
Schulz zur Wiesch et al., 2010). Since most of the resistance and
ensitivity parameters are not based on empirical measurements
e explored variation in their values in the numerical analysis, as
escribed later.
In the absence of treatment and resistance evolution, the
ndemic equilibrium of the system is given by UˆS = 1 − 1/R˜0,S
here R˜0,S = ˇS/ is the basic reproductive number (Anderson
nd May, 1991) of sensitive strains in the absence of treatment,
nd where the caret indicates an equilibrium state. Fig. 2 shows
he population dynamics when the system is initialised with this
estricted equilibrium. For this plot and subsequent numerical
nalyses, the parameters are as given in Table 2 unless indicated
therwise. After a period of time, the resistant strain rises in
requency but it is eventually supplanted by the compensated resis-
ant strain.b  Strength of resistance of R (under treatment) 0.7
k  Resistance of C (under treatment) 0.9
Fate of resistant strains
To study these dynamics further we consider the basic repro-
ductive number of each strain, disregarding mutation. For strain i
this quantity is given by
R0,i =
ˇi
 +  +
ˇi
i( + )
(1)
(see Appendix A), where ˇi is the strain-speciﬁc transmission
parameter and  i is the strain-speciﬁc recovery rate under treat-
ment. Applying the competitive exclusion principle (Bremermann
and Thieme, 1989; Levin and Pimentel, 1981) the strain with the
highest R0,i value is ultimately favoured by natural selection. The
set of basic reproductive numbers under the model constitutes a
ﬁtness landscape over the three phenotypes; this ﬁtness landscape
can be viewed as a function of the rates of treatment f and testing
 (Fig. 3).
To study the effect of the treatment rates we  consider two  quan-
tities at equilibrium: ﬁrst, the prevalence of infection, which is
given by 1 − Xˆ , and second, the prevalence of resistance among
infections, which is given by 1 − (UˆS + TˆS)/(1 − Xˆ). When only a sin-
gle treatment is available ( = 0) the prevalence of infection barely
decreases as the fraction treated f increases, but the prevalence of
resistance rapidly rises to the maximum of 100% at an extremely
low treatment rate (Fig. 4A). When an alternative treatment is avail-
able ( > 0), the prevalence of resistance again rises to near theTime (years)
Fig. 2. Numerical solution of population (log 10 scale) against time under the simple
model. Here, the parameters are as given in Table 2 with f = 0.2 ( = 0.5) and  = 0.
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rig. 3. The ﬁtness landscape of different phenotypes with ﬁtnesses given by strain
ecovery  rates substituted). The ﬁgure shows alternative landscapes under three po
iven  in Table 2, with  = 0.02 (left),  = 0.2 (middle) and  = 0.8 (right).
The interaction between the treatment proportion f and the
esistance testing parameter  can be further investigated by
onsidering pairs leading to (a) disease eradication, (b) endemic
isease with the sensitive strain and (c) endemic disease with the
ompensated resistant strain. Assuming that the mutation rates are
ow enough that the equilibrium is largely determined by compet-
tive exclusion, we can ﬁnd the boundaries corresponding to these
hree outcomes. Eradication occurs when all three basic reproduc-
ive numbers are below 1, which occurs in our case when R0,S < 1 and
0,C < 1. The sensitive strain exists at equilibrium when R0,S > 1 and
0,S > R0,C; the compensated resistant strain exists at equilibrium
hen R0,C > 1 and R0,C > R0,S. The uncompensated resistant strain
ever has the highest ﬁtness under our model settings and does
ot survive to equilibrium. This condition holds under the assump-
ion that k > b. We  can then ﬁnd boundaries in the (, f) space
eparating these outcomes (expressions and derivations are given
n Appendix B). In Fig. 5 we show these boundaries and overlay
umerically obtained equilibria when mutation is included in the
rocess.In Fig. 6, we explore how the boundaries in Fig. 5 shift as
arameters are varied, namely the basic reproductive number of
he sensitive strain without treatment R˜0,S , the resistance of the
ompensated type k, drug efﬁcacy in sensitive cases , and
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ig. 4. Equilibrium prevalence of disease and resistance as a function of the proportion
esistance. Parameters are as given in Table 2 with  = 0 (left) and  = 0.5 (right).iﬁc basic reproductive numbers R0,i (Eq. (1) with strain-speciﬁc transmission and
 values of the proportion of cases detected and treated (f = 0, 0.6, 1). Parameters are
the residual cost of resistance after compensation has occurred c.
The basic reproductive number has a strong effect on the boundary
separating eradication from ﬁxation of the compensated resistant
genotype – lower R˜0,S makes eradication achievable with lower
treatment fractions f and  (Fig. 6, top left). The drug sensitivity
parameter  also strongly affects the eradication boundary – more
powerful drugs increase the possibility of eradication (Fig. 6, bot-
tom right). In contrast, that boundary does not shift much when
varying the strength of resistance k of the compensated-resistant
type, C (Fig. 6, top right). This eradication boundary is also rela-
tively insensitive to variation in c, the residual cost of resistance
after compensation (Fig. 6, bottom left). The boundary between
sensitive and compensated resistant strains ﬁxing in the popula-
tion, however, is strongly affected by this parameter. This boundary
is unaffected by the underlying basic reproductive number R˜0,S
and only slightly affected by compensated resistance k and drug
sensitivity .
An extension with double resistanceThe model above was kept simple to aid our understanding of
how drug resistance is difﬁcult to overcome when compensatory
mutation lowers the cost of resistance. Here, we  will extend the
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 of cases treated f. Solid curves: disease prevalence; dashed curves: prevalence of
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Fig. 5. Phase diagram showing regions of eradication (“X”), ﬁxation of compen-
sated resistant strain (“C”) and ﬁxation of sensitive strain (“S”) over treatment
fraction, f and fraction of cases tested for resistance, . Numerical equilibrium
results indicated with letters (“X, C, S”) and theoretically derived boundaries shown
as  curves: f ∗
C,1 (indicating where R0,C = 1; dashed), f
∗
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This dependence is more pronounced when resistance can evolveolid), and f ∗
S,C
(indicating where R0,C = R0,S; dotted). Parameters are as shown in
able 2.
odel to show how it is even harder to eradicate a disease under
ompensatory mutation when resistance to the second-line drug
an arise.
For this model, we assume that resistance to the second drug
lready comes with a reduced cost of resistance. We  consider only
trains of type S and C with respect to the second treatment because
n the ﬁrst model the uncompensated resistant strain never has the
ighest ﬁtness and never survives to equilibrium. The dynamic vari-
bles of this model are given by two symbols; the resistance states
or the ﬁrst-line and second-line drugs are given by the ﬁrst and
econd positions respectively. For instance, doubly sensitive strains
re labelled SS and strains resistant to both drugs are either RC or
C depending on whether cost-compensation has occurred in the
ene conferring resistance to the ﬁrst drug. Again, we  assume that
he ﬁrst-line drug is used by itself, and that the second-line drug is
sed instead for cases that are tested and found to be resistant to
he ﬁrst drug.
For simplicity, we assume that the second drug is as efﬁcacious
s the ﬁrst in the absence of resistance, and that there is no pheno-
ypic interaction between the resistance loci. Let k be the degree of
esistance conferred by the compensated resistance mutation with
espect to the second-line drug.
The differential equations of the model and a diagram illus-
rating these dynamics are given in Appendix C. We  analyse this
odel by again considering the basic reproductive number, though
he calculations are longer because the system is larger and more
omplex. The appendix also gives these details.
As before, resistant (and compensated) strains reach ﬁxation
n a large proportion of the parameter space (Fig. 7). Again, a
ritical boundary of interest is the one that separates eradication
nd compensated resistance (CC or CS)  at equilibrium. This criti-
al boundary is sensitive to two resistance parameters: k and k,
enoting resistance to the ﬁrst and second drugs respectively when
he cost of resistance is low. When both of these parameters are
igh, eradication is precluded. When these parameters are lower
under roughly 0.44 for the parameters we used; see Eq. (5)), the
ffect of the boundary depends on which of these is larger. When
 > k so that compensated resistance against drug 1 is “stronger”
han that against drug 2, then eradication is only possible for highcs 5 (2013) 164–173
rates of both treatment with the ﬁrst therapy and resistance test-
ing (Fig. 7, top left). Otherwise, when k < k, eradication is possible
when again a high proportion of cases are treated with the ﬁrst
drug, but only a small fraction of these are tested for resistance
(Fig. 7, top right). In the latter case, it may  seem strange at ﬁrst
that eradication could be facilitated by making less effort in testing
for resistance; this effect arises because if the second resistance is
more powerful than the ﬁrst, it is better to favour use of the ﬁrst
drug.
The eradication boundary again is strongly inﬂuenced by the
underlying basic reproductive number R˜0,S (Fig. 7 bottom left),
and to a lesser extent the drug efﬁcacy  in sensitive cases
(Fig. 7 bottom right). This is similar to observations for the simple
model.
Discussion
We  have developed an epidemiological model to describe how
a bacterial population can transition from being drug sensitive
to being irreversibly resistant due to compensatory mutation.
For parameter values of interest, there is generally no rever-
sion to sensitivity because the cost of resistance is compensated
by a mutation lowering the cost (Andersson and Hughes, 2010;
Handel et al., 2006). This general dynamical behaviour has been
described as an evolutionary lobster trap because bacteria evolve
towards a resistant state while antibiotics are applied, and by
virtue of compensatory mutations cannot easily revert to sen-
sitivity in the absence of the drug (Bergstrom and Feldgarden,
2008; Tanaka and Valckenborgh, 2011). Here, we have explored
this evolutionary phenomenon in an epidemiological context
with an explicit model of a ﬁrst-line and second-line treat-
ment when cases can be tested for resistance to the ﬁrst
drug.
With the availability of only a single treatment, even a mod-
erate to low rate of treatment with the primary drug strongly
drives the system to the compensated resistant state. A low treat-
ment rate leads the system to ﬁxation of the sensitive phenotype.
However, the threshold treatment rate for tipping the population
towards sensitive cases is so low that hardly anyone would be
treated, defeating the purpose of deploying that drug. With the
availability of a second drug, we  found regions in the parameter
space that allow either ﬁxation of sensitives or disease eradication.
In general, eradication requires very high levels of treatment and
sometimes high levels of susceptibility-testing. Again, ﬁxation of
sensitives is possible with ineffectively low treatment rates. If resis-
tance can develop against the second-line drug, the region in which
compensated resistance takes hold is enlarged even further. Thus,
compensatory mutation lowering the cost of resistance is likely
to become a major challenge to the control of disease and drug
resistance (Bergstrom and Feldgarden, 2008; Schrag and Perrot,
1996; Andersson and Hughes, 2010; Tanaka and Valckenborgh,
2011).
The rates of treatment and susceptibility-testing required to
eradicate disease are strongly affected by the “intrinsic” basic
reproductive number (for sensitives in the absence of treatment)
and by the efﬁcacy of the drug in sensitive cases. The erad-
ication threshold is weakly inﬂuenced by the residual cost of
resistance after compensation (c), and not at all by the degree
of resistance in the R strain (parameter b, which does not appear
in the eradication boundary). The eradication boundary is inﬂu-
enced by the degree of resistance in the compensated strain (k).against the second-line drug. Whether testing for resistance aids
eradication in this case depends on whether resistance is more
powerful against the ﬁrst-line drug (then test often) or against the
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aig. 6. Phase diagram showing the boundaries separating eradication, ﬁxation of C
ffects  of varying the basic reproductive number of untreated sensitives R˜0,S (top lef
 (bottom left), and drug efﬁcacy in sensitive cases  (bottom right). Note that in t
econd-line drug (then test rarely). It is therefore important to esti-
ate these parameters empirically to evaluate the possibility of
radication.
Alternatively, there is no eradication of the disease from the pop-
lation. If the second-line drug is used sparingly while resistance
o the ﬁrst-line drug becomes entrenched due to compensatory
utation, then we envisage a scenario in which the ﬁrst-line
rug is abandoned and the second-line drug becomes used rou-
inely while a third-line drug is held in reserve as the second-line
rug was previously. This treadmill-like dynamic requires new
rugs to be constantly developed, and can be slowed down
nly by using the reserve drug rarely to avoid resistance to
t.
Our model contrasts with that of Wang and Lipsitch (2006)
ho considered the optimal timing for switching from one drug to
nother. They noted that switching to an alternative drug within the
ame class of antibiotic, would lead to resistance evolving quickly
gainst the second drug. In our model the second drug is always
vailable for resistant cases, rather than asking when to switch
rom using one therapy to another. One way to view this difference
s that here we have an ideal scenario with perfect information
bout resistance for the tested cases in the sense that the test isﬁxation of S as functions of treatment fractions  and , as in Fig. 5. We show the
istance of C under treatment k (top right), the cost of resistance after compensation
 right panel, b < k by assumption.
assumed to be completely accurate. If the information on resistance
is imperfect, the boundary for eradication would be even harder
to cross. We  note that bacteriological drug susceptibility-testing
is costly and performing the test at a high rate may  be impracti-
cal. Genotypic approaches involving sequencing of gene targets are
less reliable but also less costly (Parrish and Carroll, 2011). Techno-
logical advances in this direction may  increase the effectiveness
of controlling resistance along the lines modelled in this study.
In addition to drug susceptibility-testing, the health costs include
the cost of the drugs themselves. Considering such costs should
facilitate efforts to devise optimal strategies for control of disease
and drug resistance (McGowan, 2001; Cosgrove and Carmeli, 2003).
Our model could be extended in various directions. For instance,
it could be made epidemiologically richer by including recovery
with immune memory and other infection-speciﬁc details. Another
missing element here is recombination. Day and Gandon (2012)
and Wijngaarden et al. (2005) showed that recombination facili-
tates the evolution of compensated resistance. Under the model
of Day and Gandon (2012) there is a critical recombination rate
above which compensated resistance goes to ﬁxation. The effect
of recombination in a multi-drug system would be worth investi-
gating further. Related to this point is the possibility of deploying
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Fig. 7. Extended model with double resistance. Top: phase diagram with boundaries separating regions of eradication (“X”) from ﬁxation of different strains:
compensated resistant to both drugs (“CC”), compensated resistant to the ﬁrst-line drug but sensitive to the second (“CS”) and sensitive to both drugs (“SS”). The-
oretically derived boundaries over treatment fraction f and fraction of cases tested for resistance : f ∗
CC,1 (indicating where R0,CC = 1; solid black), f
∗
CS,1 (indicating
where R0,CS = 1; solid grey, only in the top right panel), f ∗ (indicating where R0,CS = R0,CC; dashed), f ∗ (indicating where R0,SS = R0,CS; dotted). The very short solid
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 = 0.4.
ultiple ﬁrst-line treatments or drug combinations (Bonhoeffer
t al., 1997) which may  be effective in delaying resistance if appro-
riately implemented (Bergstrom and Feldgarden, 2008; Boni et al.,
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ward to YW.ppendix A. Strain-speciﬁc basic reproductive values
We  obtain the basic reproductive number for a single strain
sing the next generation matrix approach (Diekmann et al., 2010)SS,CS
ack curves is given for completeness. Bottom: the effects of varying parame-
ess indicated otherwise. Top right: k = 0.3, k = 0.4. Other three panels: k = 0.9,
as follows. First, we specify a reduced dynamical system for a partic-
ular strain i consisting of the infectious variables only, and linearise
it around the disease-free equilibrium (0, 0) for the reduced system,
leading to
d	U/dt = ˇi 	U + ˇi 	T −  	U −  	U
d	T/dt =  	U − i 	T .
Second, construct the transmission matrix associated with this sys-
tem by taking into account only the terms that account for new
infections. In this case, we have
T =
(
ˇi ˇi
0 0
)since only these terms correspond to the generation of new infec-
tions by interacting with the population of susceptibles. Third,
construct the transition matrix associated with the same linearised
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educed system, which accounts for all transitions between the
nfected variables and possible mortality:
 =
(
−  −  0
 −i
)
.
he next generation matrix is then given by
KL = −T ˙−1
= 1
i( + )
(
ˇi (i + ) ˇi ( + )
0 0
)
.
he basic reproductive number is the largest eigenvalue of this
atrix, given by
0,i =
ˇi(i + )
i( + )
. (2)
he sign of R0,i − 1 determines the stability of the disease-free equi-
ibrium (Diekmann et al., 2010). The basic reproductive number R0,i
an be interpreted biologically as follows. An individual in state U
ill spend a period of time ( + )−1 in this state, during which (s)he
enerates ˇi ( + )−1 new infections, and then a fraction /( + )
oves to state T, where (s)he will spend an amount of time −1
i
,
uring which ˇi 
−1
i
new infections occur.
ppendix B. Critical boundaries in the (f, ) space
Here, we consider three critical boundaries separating regions
f the parameter space into three possible equilibrium states. We
rst replace  with f/(1 − f) using the relation f = /( + ). The ﬁrst
oundary, f ∗S,1, occurs when R0,S = 1, at which
S
(
1 − f ∗S,1

+
f ∗S,1
S
)
= 1;
he second, f ∗C,1, occurs when R0,C = 1, givingC
(
1 − f ∗C,1

+
f ∗C,1
C
)
= 1;
ig. 8. Model structure for the extended model with double resistance. Variables and ra
athogen strains, and the dotted arrows indicate conversion between them. Solid arrows 
he  U, T and T .cs 5 (2013) 164–173 171
the third, f ∗S,C , occurs when R0,S = R0,C, giving
ˇS
(
1 − f ∗S,C

+
f ∗S,C
S
)
= ˇC
(
1 − f ∗S,C

+
f ∗S,C
C
)
.
Rearranging these equations we  obtain
f ∗S,1 =
S( − ˇS)
ˇS( − S)
,
f ∗C,1 =
C ( − ˇC )
ˇC ( − C )
,
f ∗S,C =
ˇS − ˇC
ˇC (/C − 1) − ˇS(/S − 1)
,
which can be expressed as functions of  by substituting in the
primary parameters (Table 2). Note that since we assume b < k and
the boundary f ∗C,1 does not depend on b, this is the threshold for
eradication.
Appendix C. Extended model with double resistance
Variables and dynamics
In the extended model, we have six different pathogen strains
i ∈ {SS,  RS,  CS,  SC,  RC,  CC}, which can be divided into eighteen dis-
joint subsets according to whether they are treated and what they
are treated with (U untreated, T treated with the ﬁrst-line drug, T
treated with the second-line drug). Again, X denotes the uninfected
fraction. Fig. 8 gives a schematic of this new process, and we can
describe the dynamics through a system of differential equations.
For example, for untreated cases resistant to the ﬁrst-line drug but
sensitive to the second-line drug,
dURS
dt
= ˇRSX(URS + TRS + TRS) − URS − (1 − )URS
− (1 + 2)URS + 5URC − URS,where  represents the recovery rate, the i parameters are the
conversion rates and ˇRS is the transmission rate for strain RS.  The
other equations can be speciﬁed similarly.
tes are deﬁned in Appendix C. The dashed arrows indicate transmission of the six
show treatment rates. For clarity, the diagram does not show the recovery rates for
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Brunham, R.C., Nagelkerke, N.J., Plummer, F.A., Moses, S., 1994. Estimating the
basic reproductive rates of Neisseria gonorrhoeae and Chlamydia trachomatis:
the  implications of acquired immunity. Sex. Transm. Dis. 21 (5), 353–356.
Cosgrove, S., Carmeli, Y., 2003. The impact of antimicrobial resistance on health and
economic outcomes. Clin. Infect. Dis. 36 (11), 1433–1437.72 C.A. Saddler et al. / Ep
We  assume that the cost of resistance to each drug applies inde-
endently to the transmission rate, and that the compensatory
ffect is the same for each drug:
ˇSS = ˇ
ˇRS =  ˇ (1 − c)
ˇCS = ˇ(1 − c) = ˇSC
ˇRC =  ˇ (1 − c)(1 − c)
ˇCC =  ˇ (1 − c)2.
e  assume that the two drugs are equally effective (with single
arameter ) provided the bacteria are sensitive to them. How-
ver, the degree of (compensated) resistance can differ. This leads
o conversion and recovery rates
5 =
c
1 − c
6 =
k
1 − 
nd
SS = SC = SS = RS = CS =

1 − 
RS = RC =

1 − (1 − b)
CS = CC =

1 − (1 − k)
SC = RC = CC =

1 − (1 − k)
here  i is the recovery rate for infection with strain i under treat-
ent with the ﬁrst-line drug and i is the corresponding rate under
reatment with the second-line drug.
eproductive numbers and critical boundaries
Applying the method described in Appendix A, the transmission
atrix for this model is
 =
⎛
⎜⎜⎝
ˇi ˇi ˇi
0 0 0
0 0 0
⎞
⎟⎟⎠
nd the matrix accounting for transitions among infected variables
nd mortality becomes
 =
⎛
⎝ −  −  0 0(1 − ) −i 0
 0 −i
⎞
⎠ .
The basic reproductive number resulting from the next genera-
ion matrix is given by
0,i =
ˇi(ii + i + i − i)
ii( + )
hich simpliﬁes to
0,i =
ˇi(1 − f )

+ ˇif (1 − )
i
+ ˇif
i
. (3)
he ﬁrst, second and third components above correspond respec-
ively to contributions under no treatment, treatment under the
rst-line drug and treatment under the second-line drug. The cases
n which i ∈ {SS, SC}  must be treated slightly differently because
nfected individuals would never be treated with the second-linecs 5 (2013) 164–173
drug because they are sensitive to the ﬁrst drug. For these two
strains
R0,i =
ˇi(1 − f )

+ ˇif
i
.
Similarly to the simple model, when resistance comes with a cost
that can be compensated by a mutation, the model becomes a con-
test between sensitive (S) and resistant-compensated (C) strains.
We therefore consider the basic reproductive numbers for SS,  CS,
CC; strain SC can be neglected because it can only dominate a
population when a large proportion of cases are treated by the
second-line but not the ﬁrst-line drug, which does not occur under
our model.
The eradication boundary is found by setting R0,i = 1. The bound-
aries for CC and CS determine whether eradication is possible.
Where there is compensated resistance against the ﬁrst drug, a
boundary (at which R0,CS = R0,CC) separates whether there is resis-
tance against the second drug. Where treatment rates are low
enough to maintain sensitivity to the ﬁrst drug, a boundary (at
which R0,CS = R0,SS) separates whether there is compensated resis-
tance against the ﬁrst drug. The parameter space then becomes
divided into four possible equilibrium states (Fig. 7) with critical
boundaries at
f ∗CS,1 =
1
(1 − k) + k
(
1 − 
ˇ(1 − c)
)
(4)
f ∗CC,1 =
1
(1 − k) + (k − k)
(
1 − 
ˇ(1 − c)2
)
(5)
f ∗CS,CC =
c
c(1 − k) + (k − k)(1 − c) + k
(6)
f ∗SS,CS =
c
 − (1 − k)(1 − c) − k(1 − c) . (7)
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